ClinicalTrials.gov
public full text
Public Domain
FAPi Radioligand OpeN-Label, Phase 1 Study to Evaluate Safety, Tolerability and DosImetry of [Lu-177]-PNT6555; A Dose Escalation Study for TReatment of Patients With Select Solid Tumors (FRONTIER)
cholangiocarcinomacolorectal-canceresophageal-cancerhead-and-neck-squamous-cell-carcinomamelanoma-skinpancreatic-ductal-adenocarcinomasoft-tissue-sarcoma
This Phase 1 study will evaluate the safety and tolerability of \[Ga-68\]-PNT6555 and \[Lu-177\]-PNT6555 in subjects with select solid tumors that have FAP over-expression, in order to determine a recommended Phase 2 dose.
Conceptio Open Archive
Analyze & explore related research in Conceptio
Connect this record directly into your research workflow or AI agent. Explore citations across open repositories, query full text, and export structured proof bundles.
This document is indexed with metadata only: full text is not available in the archive for this record. Open the official source ↗
Related documents
- A Study of RP-3500 in Combination With Standard Radiation Therapy in People With Solid Tumor Cancer#840716
- 177Lu-PSMA-EB-01 in Patients With Metastatic Castration-resistant Prostate Cancer#1174059
- MAX-40279-01 in Patients With Advanced Solid Tumors#876016
- Evaluation of [⁶⁸Ga/¹⁷⁷Lu]HT547: Safety, Biodistribution, and Dosimetry in Solid Tumors#854980
- ARQ 197 in Subjects With Metastatic Solid Tumors#967030
Record · ID 882957
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Bring this data into your agent: Connect via MCP or API · 20 free credits to start · no card required
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive